The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Steven Yip
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; OncoHelix; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; Oncohelix; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; OncoHelix; Pfizer; Roche
Research Funding - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Merck
 
Rahul Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; Curio Science; EcoR1 Capital; Exelixis; Flare Therapeutics; Guidepoint Inc; Harpoon therapeutics; Janssen; Merck; MJH Life Sciences; Novartis; PCCTC; Pfizer; Research to Practice; Slingshot Insights; Tersera; Washington Research Foundation
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Xin Gao
Honoraria - OncLive
Consulting or Advisory Role - 858 Therapeutics; Abeona Therapeutics; ADC Therapeutics; Dendreon; Flare Therapeutics; Hinova Pharmaceuticals; Janssen; Kanaph Therapeutics; Loxo/Lilly
Research Funding - Acerand Therapeutics (Inst); ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Halda Therapeutics (Inst); Harpoon therapeutics (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Simon Pacey
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Joaquin Mateo
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Nuage Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)
Other Relationship - Nuage Therapeutics
 
Neal Shore
Stock and Other Ownership Interests - Photocure
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; ImmunityBio; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Nusano; Pfizer; Photocure; PlatformQ Health; Promaxo; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Wassim Abida
Honoraria - Aptitude Health; Clinical Education Alliance; Medscape; OncLive/MJH Life Sciences; Pfizer; Prostate Cancer Foundation; Roche; theMedNet; touchIME
Consulting or Advisory Role - AstraZeneca/MedImmune; Boundless Bio; Clovis Oncology; Daiichi Sankyo; DualityBio; Endeavor BioMedicines; IDEOlogy Health; Janssen; K36 Therapeutics; Laekna Therapeutics; MOMA Therapeutics; ORIC Pharmaceuticals; Pfizer; Tolmar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); Merus (Inst); MOMA Therapeutics (Inst); Nuvation Bio (Inst); ORIC Pharmaceuticals (Inst); TransThera Biosciences (Inst); Zenith Epigenetics (Inst)
(OPTIONAL) Uncompensated Relationships - Nuvation Bio
 
Boaz Aronson
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Neel Shah
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Massimo Squatrito
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Huifang (Ariel) Chen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yu Jiang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jane Peters
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Silvija Kraljevic
Employment - AstraZeneca
 
Michael Niedbala
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar